INBRX-109 not checked

Inhibrx Biosciences, Inc

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
2 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Conventional Chondrosarcoma, Ewing Sarcoma, Colorectal Adenocarcinoma
Main trialPhase 2
“Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.”In the company’s words, NCT04950075 on ClinicalTrials.gov

Other drugs for Ewing Sarcoma

All 11 drugs for Ewing Sarcoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 30 Sep 2025 Study of INBRX-109 in Conventional Chondrosarcoma
Phase 1Recruiting Dec 2028 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow INBRX-109

Following is part of Solo: you see every change to INBRX-109 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in